Gao H, Zhang W, Li Z, Liu W, Liu M, Zhuo Q
BMC Cancer. 2024; 24(1):1362.
PMID: 39511555
PMC: 11542389.
DOI: 10.1186/s12885-024-13117-5.
Ratnayake G, Shekhda K, Glover T, Al-Obudi Y, Hayes A, Armonis P
J Neuroendocrinol. 2024; 37(1):e13465.
PMID: 39503166
PMC: 11750320.
DOI: 10.1111/jne.13465.
Tan B, Zhang B, Chen H
Front Endocrinol (Lausanne). 2024; 15:1424839.
PMID: 39411312
PMC: 11474919.
DOI: 10.3389/fendo.2024.1424839.
Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M
Int J Mol Sci. 2024; 25(16).
PMID: 39201255
PMC: 11354135.
DOI: 10.3390/ijms25168568.
Schmidt M, Hinterleitner C, Singer S, Lauer U, Zender L, Hinterleitner M
Cancers (Basel). 2023; 15(17).
PMID: 37686593
PMC: 10486951.
DOI: 10.3390/cancers15174316.
Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest. 2023; 47(1):35-46.
PMID: 37581846
PMC: 10776682.
DOI: 10.1007/s40618-023-02170-9.
A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.
Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N
J Clin Med. 2023; 12(15).
PMID: 37568540
PMC: 10420169.
DOI: 10.3390/jcm12155138.
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements.
Merola E, Grana C
Cancers (Basel). 2023; 15(11).
PMID: 37296936
PMC: 10251822.
DOI: 10.3390/cancers15112975.
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
Eads J, Halfdanarson T, Asmis T, Bellizzi A, Bergsland E, Dasari A
Endocr Relat Cancer. 2023; 30(8).
PMID: 37184955
PMC: 10388681.
DOI: 10.1530/ERC-22-0206.
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care.
Del Rivero J, Mailman J, Rabow M, Chan J, Creed S, Kennecke H
Endocr Relat Cancer. 2023; 30(7).
PMID: 37017232
PMC: 10326633.
DOI: 10.1530/ERC-22-0226.
Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues.
Rosiek V, Janas K, Kos-Kudla B
Biomedicines. 2023; 11(3).
PMID: 36979820
PMC: 10044914.
DOI: 10.3390/biomedicines11030842.
What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?.
Stiefel R, Lehmann K, Winder T, Siebenhuner A
BMC Cancer. 2023; 23(1):148.
PMID: 36782152
PMC: 9926660.
DOI: 10.1186/s12885-023-10567-1.
Skin manifestations of neuroendocrine neoplasms: review of the literature.
Walecka I, Owczarek W, Ciechanowicz P, Dopytalska K, Furmanek M, Szczerba M
Postepy Dermatol Alergol. 2022; 39(4):656-661.
PMID: 36090712
PMC: 9454360.
DOI: 10.5114/ada.2021.112073.
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study.
Campana C, Van Koetsveld P, Feelders R, de Herder W, Iyer A, van Velthuysen M
Eur J Endocrinol. 2022; 187(3):399-411.
PMID: 35895707
PMC: 9346267.
DOI: 10.1530/EJE-22-0339.
Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
Zwirtz K, Hardt J, Acker G, Baur A, Pavel M, Huang K
Pharmaceutics. 2022; 14(6).
PMID: 35745849
PMC: 9227135.
DOI: 10.3390/pharmaceutics14061278.
Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Kaliszewski K, Ludwig M, Greniuk M, Mikula A, Zagorski K, Rudnicki J
Cancers (Basel). 2022; 14(8).
PMID: 35454934
PMC: 9030061.
DOI: 10.3390/cancers14082028.
Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives.
Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S
World J Gastrointest Surg. 2022; 14(2):78-106.
PMID: 35317548
PMC: 8908345.
DOI: 10.4240/wjgs.v14.i2.78.
First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.
Levy S, Verbeek W, Eskens F, van den Berg J, de Groot D, van Leerdam M
Ther Adv Med Oncol. 2022; 14:17588359221077088.
PMID: 35251315
PMC: 8891910.
DOI: 10.1177/17588359221077088.
Heterogeneity of Small Intestinal Neuroendocrine Tumors Metastasis: Biologic Patterns of a Series with Virchow's Node Involvement.
Wedin M, Tsoli M, Wallin G, Janson E, Koumarianou A, Kaltsas G
Cancers (Basel). 2022; 14(4).
PMID: 35205660
PMC: 8869999.
DOI: 10.3390/cancers14040913.
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi M
JAMA Netw Open. 2022; 5(2):e220290.
PMID: 35201309
PMC: 8874344.
DOI: 10.1001/jamanetworkopen.2022.0290.
